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The genetic defect in Friedreich’s ataxia (FRDA) is the hyperexpansion of a GAA•TTC triplet
in the first intron of the FXN gene, encoding the essential mitochondrial protein frataxin.
Histone post-translational modifications near the expanded repeats are consistent with
heterochromatin formation and consequent FXN gene silencing. Using a newly developed
human neuronal cell model, derived from patient-induced pluripotent stem cells, we find
that 2-aminobenzamide histone deacetylase (HDAC) inhibitors increase FXN mRNA levels
and frataxin protein in FRDA neuronal cells. However, only compounds targeting the class I
HDACs 1 and 3 are active in increasing FXN mRNA in these cells. Structural analogs of the
active HDAC inhibitors that selectively target either HDAC1 or HDAC3 do not show similar
increases in FXN mRNA levels. To understand the mechanism of action of these com-
pounds, we probed the kinetic properties of the active and inactive inhibitors, and found
that only compounds that target HDACs 1 and 3 exhibited a slow-on/slow-off mechanism
of action for the HDAC enzymes. HDAC1- and HDAC3-selective compounds did not show
this activity. Using siRNA methods in the FRDA neuronal cells, we show increases in FXN
mRNA upon silencing of either HDACs 1 or 3, suggesting the possibility that inhibition of
each of these class I HDACs is necessary for activation of FXN mRNA synthesis, as there
appears to be redundancy in the silencing mechanism caused by the GAA•TTC repeats.
Moreover, inhibitors must have a long residence time on their target enzymes for this activ-
ity. By interrogating microarray data from neuronal cells treated with inhibitors of different
specificity, we selected two genes encoding histone macroH2A (H2AFY2) and Polycomb
group ring finger 2 (PCGF2) that were specifically down-regulated by the inhibitors target-
ing HDACs1 and 3 versus the more selective inhibitors for further investigation. Both genes
are involved in transcriptional repression and we speculate their involvement in FXN gene
silencing. Our results shed light on the mechanism whereby HDAC inhibitors increase FXN
mRNA levels in FRDA neuronal cells.
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INTRODUCTION
Friedreich’s ataxia (FRDA, OMIM 229300) is an autosomal reces-
sive neurodegenerative disorder caused by a GAA•TTC triplet
repeat expansion in an intron of the nuclear FXN gene, which
encodes the essential mitochondrial protein frataxin (1). Frataxin
is involved in the assembly of iron–sulfur clusters, and their trans-
fer to mitochondrial enzymes and components of the electron
transport chain [reviewed in Ref. (2)]. Unaffected individuals have
between 6 and 30 GAA•TTC repeats, whereas affected individu-
als have from approximately 70 to more than 1,000 triplets. A
small number of patients are compound heterozygous, with one
expanded FXN allele and an inactivating point mutation on the
second allele. The effect of the GAA•TTC expansion mutation is
to reduce expression of frataxin at the level of transcription (3),
through the formation of heterochromatin and subsequent gene
silencing (4–8). Frataxin insufficiency leads to decreased activity
of iron–sulfur cluster enzymes, mitochondrial iron accumulation,
and resultant cell death, with the primary sites of pathology being
the large sensory neurons of the dorsal root ganglia and the den-
tate nucleus of the cerebellum (9). Non-neuronal tissues are also
involved in the disease. Cardiomyopathy is common among FRDA
patients and diabetes is found in 10% of FRDA patients (10, 11).
Approximately, 60% of patients succumb to the disease in early
adulthood due to cardiomyopathy (12). Currently, there is no
approved and effective therapy for this disorder.
The epigenetic basis for transcriptional silencing in FRDA is
now well established (5–8, 13, 14). The GAA•TTC repeat expan-
sion is correlated with both increased DNA methylation in the
region of FXN intron 1 immediately upstream of the GAA•TTC
repeats (6, 7, 15), as well as with reduced histone acetylation
and increased histone trimethylation at the FXN promoter (6,
8), and in intron 1 adjacent to the repeats (5–7). A number of
hypotheses have been put forward to explain how the GAA•TTC
repeats induce heterochromatin formation, but this remains an
open question. Attractive hypotheses for induction of silencing
include RNA-mediated silencing, where either sense or antisense
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transcription of the repeats initiates an RNA-induced silencing
complex (8). Alternatively, the repeats could form non-B DNA
structures, which induce silencing. An extensive literature doc-
uments the formation of triplex or “sticky DNA” structures by
GAA•TTC repeat DNA (16). Lastly, recent evidence suggests
that R-loops can mediate heterochromatin formation and gene
silencing (17).
Based on this large body of evidence for the mechanism
of gene silencing in FRDA [reviewed in Ref. (13, 18, 19)], it
was reasonable to propose epigenetic-modifying compounds as
a potential therapeutic strategy for FRDA. In an early study,
Sarsero and colleagues (20) tested sodium butyrate for its abil-
ity to increase FXN mRNA expression, but only a modest effect
was observed. Our laboratory reported a screen of a panel of
commercially available histone deacetylase (HDAC) inhibitors
in FRDA lymphoblasts and we found that only the benza-
mide BML-210 [N 1-(2-aminophenyl)-N 8-phenyloctanediamide]
produced a significant increase of FXN mRNA expression in
FRDA lymphoblasts (5). Similarly, Festenstein and co-workers
have reported that the sirtuin protein deacetylase inhibitor
nicotinamide (vitamin B3) also increases FXN mRNA levels
in FRDA lymphoblasts, in a FRDA mouse model (14), and
recently in circulating lymphocytes from nicotinamide-treated
patients (21).
Our laboratory identified a 2-aminobenzamide HDAC
inhibitor, 4b [N 1-(2-aminophenyl)-N 7-phenylheptanediamide],
which was shown to act on FRDA primary lymphocytes to sig-
nificantly increase acetylation of H3K14, H4K5, and H4K12 in
the FXN upstream GAA•TTC region and to significantly increase
FXN mRNA levels (5). Further development of this family of 2-
aminobenzamide HDAC inhibitors identified other compounds,
which have shown efficacy in FRDA patient cells and in mouse
models (22–27). These compounds produce significant short-
term increases in histone acetylation and FXN mRNA and frataxin
protein expression in FRDA primary lymphocytes and brain
and heart tissues of FRDA KIKI mice (23, 26), and have also
shown efficacy in a transgenic mouse model for FRDA (27).
More recently, we showed efficacy of a 2-aminobenzamide HDAC
inhibitor (HDACi 109) in neuronal cells derived from FRDA-
induced pluripotent stem cells (iPSCs) (28). This compound was
taken into a Phase Ib clinical trial in FRDA patients, where drug
treatment lead to increases in FXN mRNA and histone acety-
lation at the FXN gene in peripheral blood mononuclear cells.
Interestingly, the concentration of drug required to induce epi-
genetic changes in neuronal cells is comparable to the exposure
in patients required to observe increases in histone acetylation
and gene activation. While the 2-aminobenzamides are promising
therapeutics for FRDA, further development of this compound
class will be necessary to identify molecules for chronic use. Here,
we explore the mechanism of action of this compound class
and our efforts to identify improved molecules for future clinical
study.
MATERIALS AND METHODS
MATERIALS
Recombinant human HDAC1 and HDAC3/NCoR2, expressed in
baculovirus, were purchased from BPS Bioscience (San Diego, CA,
USA). The HDAC inhibitors 109, 136, 3, 233, 966, and Click-1 were
synthesized as previously described (25, 26, 29–31).
HDAC ACTIVITY ASSAYS
The deacetylase activities of HDACs 1 and 3 were measured
by assaying enzyme activity using Lys-C peptidase and the syn-
thetic substrate acetyl-Lys(Ac)-AMC, as previously described (22).
The HDAC enzymes produce deacetylated lysine-AMC, which
can be cleaved by the peptidase to generate free fluorogenic 4-
methylcoumarin-7-amide (MCA). MCA fluorescence is read with
an excitation wavelength of 370 nm and emission wavelength of
460 nm, using a Tecan M200 96 well-plate reader (San Jose, CA,
USA). All HDAC assays were performed in 96 well, non-binding
plates (Greiner Bio-one, NC, USA) in 50 mM Tris–HCl buffer (pH
8.0), containing 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl, and
0.1 mg mL−1 bovine serum albumin at ambient temperature. To
determine inhibition mechanisms and associated kinetic values, a
series of enzyme progression curves for HDACs 1 and 3, at differ-
ent concentrations of inhibitors, were generated by adding 100 ng
of each enzyme into separate reaction mixtures containing 50µM
acetyl-Lys(Ac)-AMC substrate (five times the Km) and 2 mU of
Lys-C peptidase developer for a period of 1 h. Data from each pro-
gression curve, at different inhibitor concentrations, were fit using
the non-linear regression program KaleidaGraph to the integrated
rate equation for slow-binding inhibitors:
[F] = vst + (v0 − vs)
(
1− exp (−kobst )
)
/kobs (1)
where [F] is the amount of MCA fluorophore generated, rep-
resented in arbitrary fluorescence units (AFU, r), which is pro-
portion to the deacetylated substrate at time t. v0 and vs are
the initial and the final steady-state velocities, respectively. kobs
is the apparent first-order rate constant obtained by the best fit to
the data. The kobs values were then plotted against the inhibitor
concentrations for which each kobs value was obtained. For mecha-
nism 1 (see below), the relationship between kobs and the inhibitor
concentration is linear:
kobs = k−1 + k1 [I] / (1+ [S] /Km) (2)
and
Ki = k−1/k1 (3)
For mechanism 2, the relationship between kobs and the inhibitor
concentration is hyperbolic:
kobs = k−2 + k2 [I] /
[
[I ]+ K ∗i (1+ [S] /Km)
]
(4)
and
Ki = Ki∗ [k−2/ (k2 + k−2)] (5)
where K ∗i is the stable complex forming constant and K i is the
overall final inhibitory constant for the entire process.
DERIVATION OF FRDA NEURONAL CELLS, qRT-PCR, ANDWESTERN
BLOTTING
All methods for iPSC derivation (32) and neuronal differentia-
tion (28, 33) have been presented. Two patient fibroblast lines
Frontiers in Neurology | Neurogenomics March 2015 | Volume 6 | Article 44 | 2
Soragni et al. HDAC inhibitors in Friedreich’s ataxia
(GM03816 and GM04878 from the Coriell repository) and one
unaffected fibroblast line (GM08333 from the Coriell repository)
were used to derive iPSCs and neurons (as approved by the
University of California, San Diego, Human Research Protection
Program, Embryonic Stem Cell Research Oversight Committee,
project #110235ZO). Quantitative RT-PCR was performed as
described (28), with the following primer pairs:
FXN : 5′-CAGAGGAAACGCTGGACTCT-3′ and 5′-AGCCAGAT
TTGCTTGTTTGG-3′
HDAC1: 5′-CCGCATGACTCATAATTTGC-3′ and 5′-GGTCATC
TCCTCAGCATTGG-3′
HDAC2: 5′-CGCATGACCCATAACTTGC-3′ and 5′-TGTCATTT
CTTCGGCAGTGG-3′
HDAC3: 5′-GTATGAAGTCGGGGCAGAGA-3′ and 5′-GGCTGG
AAAAGGTGCTTGTA-3′
PCGF2: 5′-AGCATCAGGTCTGACAAAACAC-3′ and 5′-GCCGC
CGTTTCATCTCATC-3′
H2AFY2: 5′-GCGGCAGTCATTGAGTACCTG-3′ and 5′-CAAGA
TGTGTCTCGGGGCTAT-3′
Data were normalized to RNA concentration and p values
calculated using the t -test. Western blotting was performed as
described (28), with antibodies to HDACs 1, 2, and 3 from
Abcam (ab7028, ab7029, ab7030, respectively), used at a dilution
of 1:5000. RNA polymerase II signal was used as a recovery stan-
dard and antibodies against RNA polymerase II were purchased
from Millipore (05-952) and used at a dilution of 1:2000. Pro-
tein concentrations were determined with the BCA assay (Thermo
Scientific).
siRNA-MEDIATED DOWN-REGULATION OF HDACs 1, 2, AND 3
siRNAs were purchased from Life Technologies (HDAC1 siRNA
ID # 120418, HDAC2 siRNA ID # 120208, HDAC3 siRNA ID
#120349). Neuronal cells were allowed to differentiate for 10 days
in Neurobasal A medium supplemented with N2 and B27 (all
from Life Technologies) before addition of siRNAs to a final con-
centration of 12 nM and lipofectamine RNAiMAX transfection
reagent (Life Technologies). The next day media was changed and
cells were allowed to recover for another 24 h. At day 12 of dif-
ferentiation, another round of siRNA transfection was performed
as above. Cells were collected for qRT-PCR and western blotting
analyses 96 h after the first siRNA treatment.
CHROMATIN IMMUNOPRECIPITATION
Chromatin immunoprecipitation (ChIP) is described in detail in
Soragni et al. (28). The antibodies used in this study are the same
as the ones indicated in the western blotting section, each used at
a concentration of 5µg mL−1. Samples were quantified in trip-
licate by real-time PCR using the standard curve method. The
DNA recovery for each region is expressed as the ratio to the DNA
recovery of GAPDH coding region. The primers used were:
FXN promoter: 5′-CCCCACATACCCAACTGCTG-3′ and 5′-G
CCCGCCGCTTCTAAAATTC-3′
UPGAA: 5′-GAAACCCAAAGAATGGCTGTG-3′ and 5′-TTCCC
TCCTCGTGAAACACC-3′
DOWNGAA: 5′-CTGGAAAAATAGGCAAGTGTGG-3′ and 5′-C
AGGGGTGGAAGCCCAATAC-3′
p21(CDKN1A): 5′-GCGTTCACAGGTGTTTCTGC-3′ and 5′-A
CATCCCGACTCTCGTCACC-3′
MYC promoter: 5′-TGCGATGATTTATACTCACAGG-3′ and 5′-
CTCCCTCTCAAACCCTCTCC-3′
GAPDH: 5′-CACCGTCAAGGCTGAGAACG-3′ and 5′-ATACCC
AAGGGAGCCACACC-3′
MICROARRAY ANALYSIS
Eight-day-old neurons were treated with DMSO or 10µM 109,
966, or 233 for 24 h. RNA purification, labeling, and hybridiza-
tion to Illumina HT-12 v4 arrays (see: http://www.illumina.com/
products/humanht_12_expression_beadchip_kits_v4.html) were
performed as previously described (32). The HT-12 array tar-
gets more than 31,000 annotated genes and splice variants, with
more than 47,000 probes [derived from the National Center for
Biotechnology Information (NCBI) Reference Sequence (RefSeq)
Release 38, November 7, 2009]. After normalization, genes differ-
entially expressed between the DMSO groups (three replicates)
and the 109-treated groups (three replicates) were identified with
a Student’s t -test at a significance level of p< 0.01 (uncorrected p
value). Genes with expression level changes greater than 2 in the
109 groups and smaller that 1.5 in the 233 or 966 groups (one
replicate per compound) were then subjected to functional anno-
tation analysis via the Database for Annotation, Visualization, and
Integrated Discovery (DAVID). Illumina probes were converted to
gene symbols using DAVID gene ID conversion tool. Microarray
data are deposited in the Gene Expression Omnibus as accession
number GSE65399.
RESULTS
ISOTYPE SELECTIVITY FOR HDAC INHIBITORS THAT INCREASE FXN
GENE EXPRESSION IN FRDA CELLS
We previously described a series of 2-aminobenzamide HDAC
inhibitors that have differential inhibitory activities against mem-
bers of the class I HDAC enzymes (25, 26). We synthesized a
series of focused chemical libraries to provide diversity in potency,
selectivity, and pharmacologic properties with the aim of devel-
oping a pharmaceutical agent for the treatment of FRDA. The
general structure exemplified by HDACi 106 (Figure 1) shows
the salient features of the pimelic 2-aminobenzamide family: the
solvent accessible or cap group (left ring), linker group (five meth-
ylenes), and zinc-binding group (2-aminophenyl). By analogy to
the hydroxamate HDAC inhibitors for which co-crystal struc-
tural information has been obtained (34, 35), and the recent
crystal structure of HDAC3 (36), the right side of the molecule
interacts with the Zn-containing active site of HDAC enzymes
while the left side is positioned to interact with protein sur-
face residues distant from the active site. Substitution at the 4-
position of the 2-aminobenzamide ring with fluorine increases
selectivity for HDAC3 inhibition by decreasing potency to inhibit
HDAC1/2 (26, 37). Large substitutions at the 5-position, such
as a phenyl or thiophene increase selectivity for HDAC1/2 over
HDAC3 (25, 29).
In recent studies, we found that only compounds that tar-
get each of the class I HDACs (HDACs 1, 2, and 3) are potent
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FIGURE 1 | Structures of the HDAC inhibitors.
activators of FXN gene expression in iPSC-derived FRDA
neuronal cells (28). To further explore the relationship between
HDAC isotype selectivity and FXN gene expression, we focus
on three compounds, 109 [N -(6-(2-aminophenylamino)-6-
oxohexyl)-4-methylbenzamide; (26, 28)], 136 [N -(6-(2-amino-4-
fluorophenylamino)-6-oxohexyl)-4-methylbenzamide; (26)], and
3 [N 1-(4-aminobiphenyl-3-yl)-N 7-phenylheptanediamide; (25)].
Compound structures are shown in Figure 1 and IC50 and K i val-
ues for inhibition of HDACs 1 and 3 are shown in Table 1. While
HDACi 109 is a potent inhibitor of both enzymes, compound 136
is much less potent than 109 with a slight selectivity for HDAC3
and 3 is a selective inhibitor for HDAC1 (25, 26).
Figure 2 presents the results of qRT-PCR analysis of FXN
mRNA levels after incubation of FRDA iPSC-derived neurons with
each of the three HDACi for 24 h. As expected from previous stud-
ies with other isotype selective compounds (28), only HDACi 109
is a potent inducer of FXN gene expression in these cells, while
compounds 136 and 3 had either no effect (3) or only a mod-
est effect (136) on FXN mRNA levels. None of these compounds
have pronounced effects on FXN gene expression in cells from
unaffected individuals (25, 26, 28). These findings are also similar
to our results with HDACi966 [(E)-N -(2-amino-4-fluorophenyl)-
3-(1-cinnamyl-1H -pyrazol-4-yl)acrylamide; ~30-fold selectivity
for HDAC3 over HDAC1/2) (37)] and 233 [N -(2-amino-5-
(2-thienyl)phenyl)-7-nicotinoylamino-heptanamide; >200-fold
selectivity for HDAC1 over HDAC3 (30)]. We conclude that simul-
taneous inhibition of HDACs 1 and 3 is necessary for reactivation
of FXN gene expression in the neuronal cell model.
In a previous study (22), we analyzed the mechanism of enzyme
inhibition for HDACi 106 for both HDAC1 and HDAC3-NCoR.
Compounds 106 and 109 are constitutional isomers of each other,
where the orientation of the “left” amide linkage is reversed in the
two molecules (Figure 1). We previously reported that compound
106 is a slow-on/slow-off inhibitor (22). There are two com-
mon mechanisms for slow-on/tight-binding inhibitors, as shown
below. Mechanism 2 differs from mechanism 1 in that a stable
enzyme-inhibitor complex (EI*) is formed, whereas no such sta-
ble intermediate is formed in mechanism 1 (38). The equations
describing these mechanisms, and the derivation of inhibition
constants, on-rates, and off-rates from progression curve HDAC
inhibition assays, are described above. Briefly, for mechanism 1,
the relationship between kobs and the inhibitor concentration is
linear, whereas for mechanism 2, the relationship between kobs and
inhibitor concentration is hyperbolic. In contrast to these mecha-
nisms, a fast-on/fast-off competitive inhibition mechanism is best
described by a plot of v i/v0 against inhibitor concentration, where
v i and v0 are the reaction velocities (deacetylation rates) in the
presence or absence of the inhibitor, respectively.
Mechanism 1
Mechanism 2
IC50 determinations showed time-dependence for inhibition
for HDAC1 109 with both HDAC1 and HDAC3-NCoR, indicat-
ing a slow-on mechanism (26). From kinetic measurements, we
showed that 109 is a slow-on/slow-off inhibitor of both enzymes,
but the on-rate of 109 is faster for HDAC1 than for HDAC3/NCoR.
Compound 109 has a K i of 32 nM for HDAC1 and a K i of
5 nM for HDAC3/NCoR2, resulting in an approximately 6-fold
selectivity for HDAC3 over HDAC1 (Table 1). Kinetic constants
for 109 are provided in Table 2. Plots of kobs versus inhibitor
concentration are provided in Figures S1–S3 in Supplementary
Material for HDACi 109, 136, and 3, respectively. Plots of kobs ver-
sus inhibitor concentration for HDACi 109 with either HDAC1 or
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Table 1 | Inhibition constants, IC50, and K i values for HDAC inhibitors and HDACs 1 and 3.
Compound IC50 HDAC1 IC50 HDAC3 Selectivity HDAC3 K i HDAC1 K i HDAC3 Selectivity HDAC3
109a 60 nM 50 nM ~1 32 nM 5 nM ~6
136a 1.14µM 560 nM ~2 630 nM 196 nM ~3
3b 127 nM 9.6µM 0.013 7 nM 2.5µM 0.028
aData from Rai et al. (26).
bData from Xu et al. (25).
FIGURE 2 | Effect of HDAC inhibitors on FXN mRNA levels in neuronal
cells. Quantitative RT-PCR analysis of FXN expression in 16-day-old FRDA
neurons after 24-h treatment with HDAC inhibitors 109, 136, and 3 at
varying concentrations. FXN mRNA levels were normalized to total RNA
concentration. Signals from DMSO-treated samples were arbitrarily set to
1. Error bars=SEM of triplicate measurements.
Table 2 | Inhibition constants for benzamide HDAC inhibitors.
Compound HDAC3 HDAC1
109 k−2=0.0025 min−1 k−2=0.0036 min−1
k2=0.0762 min−1 k2=0.121 min−1
mechanism 2 mechanism 2
136 k−2=0.0136 min−1 Fast-on/fast-off
k2=0.124 min−1 Competitive inhibition
mechanism 2 mechanism
3 k−1=0.0015 min−1 k−2=0.0017 min−1
k1=600 min-1 M−1 k2=0.1675 min−1
mechanism 1 mechanism 2
HDAC3-NCoR are best fit by the equation for mechanism 2, indi-
cating a stable EI* complex is formed with both enzymes. In other
words, 109 is a slow-on/tight-binding inhibitor of both enzymes.
In IC50 determinations, compound 136 shows a time-
dependent inhibition of HDAC3/NCoR, where the IC50 against
HDAC3/NCoR decreases from ~17µM to 560 nM over a period
of 3 h; however, no time-dependent inhibition of HDAC1
was observed with compound 136 (26). Kinetic measurements
(Table 2; Figure S2 in Supplementary Material) showed that com-
pound 136 is a fast-on/fast-off, competitive inhibitor of HDAC1
with K i of 630 nM, whereas 136 is a slow-on/slow-off, tight-
binding inhibitor of HDAC3/NCoR with K i of 196 nM, resulting
in a ~3-fold selectivity for HDAC3 over HDAC1, following inhibi-
tion mechanism 2 only for HDAC3 (Figure S2 in Supplementary
Material). The competitive inhibition mechanism for 136 with
HDAC1 is similar to the inhibition mechanism for SAHA and
other hydroxamate HDAC inhibitors that fail to activate FXN gene
expression (5, 22). Appending a phenyl group at the 5-position of
the benzamide ring of HDACi 106 (22) resulted in compound 3,
with increased selectivity for HDAC1/2 over HDAC3 (25). HDACi
3 has a ~75-fold preference for HDAC1 over HDAC3 comparing
IC50 values and a ~350-fold preference for HDAC1 over HDAC3
from K i measurements (Table 1). Similar to 109 and 136, the
kinetic data for 3 and HDAC1 (Table 2) are best fit to a slow-
on/slow-off inhibition mechanism 2, whereas the kinetic data
showed that HDACi 3 inhibits HDAC3 via mechanism 1, where no
stable complex is formed (Figure S3 in Supplementary Material).
We thus conclude that compounds that are potent activators of
FXN gene expression in FRDA cell models share a common prop-
erty of inhibition of class I HDACs through inhibition mechanism
2 and compounds that are inactive in FXN gene expression assays
fail to inhibit either HDAC1 or HDAC3 by this mechanism. This
suggests that stable target engagement is a requirement for activa-
tion of FXN gene expression and that inhibition of both HDAC1
and HDAC3 is required for FXN gene reactivation.
EFFECTS OF siRNA GENE SILENCING ON FXN mRNA
If this latter assertion is correct, then down-regulation of class
I HDAC enzyme levels in neuronal cells by siRNA methods
should yield a similar result as obtained with small-molecule
inhibitors. Figure 3 shows the effect of siRNA targeting each of
the class I HDACs with validated siRNAs, at both the mRNA level
(Figure 3A) and protein levels (Figure 3B). While siHDAC2 and
siHDAC3 reduce the mRNAs for their cognate enzymes by greater
than 70% compared to a control, scrambled siRNA, siHDAC1 was
less active, achieving only 30% knockdown. Curiously, siHDAC2
also caused a non-significant reduction in HDAC3 mRNA levels
(also seen at the protein level, Figure 3B), but not to the extent
of HDAC3 knockdown. We next monitored the effects of these
siRNAs at the level of their cognate proteins by western blot-
ting with well-established antibodies [see Materials and Methods
and Ref. (28)]. Each siRNA had significant effects on enzyme lev-
els, with clear specificity for the targeted enzyme. Only siHDAC2
appeared to also down-regulate HDAC3 as well as HDAC2, as
found for mRNA levels. With these results in hand, we moni-
tored the levels of FXN mRNA in knockdown neuronal cells.
We find that siHDAC1 and siHDAC3 were potent inducers of
FXN gene expression (Figure 3C), although FXN up-regulation
with siHDAC3 treatment did not reach statistical significance (p
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FIGURE 3 | Effects of down-regulation of HDAC enzyme levels by
siRNA on FXN mRNA. (A) Effects of siRNAs to HDACs 1–3 on the mRNA
levels for each HDAC enzyme in FRDA neuronal cells. Quantitative RT-PCR
was used to determine mRNA levels, with each mRNA arbitrarily set to 1 in
the presence of a scrambled siRNA (scram). Error bars=SEM of duplicate
biological experiments, quantified in triplicate. **p<0.01. (B) Western blots
for HDAC1, HDAC2, HDAC3, and RNA polymerase II (protein recovery
standard), after treatment with a scrambled (Scr) siRNA, or siRNAs to
HDACs 1–3 as indicated at the top of the figure. One example is shown, but
the experiment was performed twice. (C) FXN mRNA levels were
determined in FRDA neuronal cells by qRT-PCR after treatment with
scrambled (scram) or siRNAs to HDAC 1–3, as indicated (siHD1-3). Error
bars=SEM of duplicate biological experiments, quantified by qRT-PCR in
triplicate. *p<0.05. n.s., not significant, see text.
value= 0.09). In contrast, siHDAC2 did not increase FXN mRNA
to the extent observed with the other siRNAs. Previous studies
in various systems have pointed to differences between small-
molecule inhibition and protein ablation in terms of biological
outcome (39). Removing a particular HDAC enzyme from the
cell will naturally affect its interaction partners, many of which
are other HDACs or components of shared co-repressor com-
plexes (40). Thus, it is not surprising that down-regulation of
either HDAC1 or HDAC3 can result in potent increases in FXN
gene expression in FRDA cells, pointing again to the involvement
of the class I HDACs in GAA•TTC repeat-mediated FXN gene
repression.
FIGURE 4 | Class I HDACs are not detected on the FXN gene in
neuronal cells. ChIP was performed on 16-day-old neurons with antibodies
against HDAC1, HADC2, and HDAC3. The region of the promoter (Prom),
upstream (UPGAA), and downstream (DOWNGAA) of the GAA•TCC repeats
on the FXN gene were interrogated by qPCR. Data are plotted as
enrichment over the DNA recovery of the GAPDH coding region. The
recovery of CDKNA1 (p21) promoter and MYC promoter are shown as
positive controls.
LOCALIZATION OF HDAC ENZYMES ON THE FXN GENE
To ask whether the class I HDACs interact directly with the FXN
gene in FRDA neuronal cells, we performed ChIP studies. Our pre-
vious ChIP studies clearly showed increases in histone acetylation
along the FXN gene after incubation with HDAC inhibitors that
increase FXN gene expression (5, 28). We also found that hydroxa-
mates such as SAHA and TSA that are without effect on FXN gene
expression also failed to increase acetylation of histones H3 and H4
at the FXN gene locus in lymphoid cells (5), and isotype-selective
HDACi allowed us to identify lysines 9 and 27 of histone H3 as
critical residues for FXN reactivation (28). In contrast to these
clear results, ChIP studies consistently failed to provide evidence
for localization of class I HDACs either upstream or downstream
of the GAA•TTC repeats (Figure 4). Since these repeats are ubiq-
uitous in the human genome, it is not possible to assess HDAC
enzyme occupancy at the FXN repeats by ChIP, so it is conceivable
that these enzymes do localize with the repeats. Nonetheless, in
these experiments, we attempted to shear chromatin fragments to
lengths that would include the repeats when probing with primer
sets either upstream or downstream from the repeats (28, 32).
These findings are consistent with a transitory interaction between
class I HDACs and FXN gene chromatin or perhaps indicate an
indirect mechanism of action. The increase in histone acetylation
that we see upon HDACi treatment (5, 28) can be a direct effect
of inhibition of HDAC complexes residing on the FXN gene, or a
consequence of gene reactivation via a different mechanism.
DO HDAC INHIBITORS ACT DIRECTLY ON THE FXN GENE OR THROUGH
DIFFERENT GENES?
While increased histone acetylation of FXN chromatin on
treatment with our HDAC inhibitors suggests that FXN gene
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chromatin is the direct target of these compounds, an alterna-
tive hypothesis for a mechanism of action of our HDAC inhibitors
is that the active molecules cause a change in expression of a gene
or set of genes that in turn regulate FXN gene expression. To
assess this possibility, we treated FRDA neuronal cells with com-
pounds 109, 233, and 966 (10µM for 24 h) and then analyzed
global gene expression with Illumina microarrays. We established
by qRT-PCR that HDACi 109 did indeed up-regulate FXN mRNA
while the other two compounds did not [data not shown, but see
Figure 2 and Ref. (28)]. We interrogated the microarray data first
for genes that are specifically up or down-regulated by HDACi
109, with a p value<0.01, and assembled a list of 1,216 such genes
(661 genes are up-regulated and 555 genes are down-regulated;
Table S1 in Supplementary Material). Functional annotation clus-
tering of these genes using the DAVID, identified groups related to
transcription and nuclear processes, apoptosis, and mitochondrial
function (not shown). We then selected only genes that were up-
regulated or down-regulated by at least 2-fold and subtracted from
this list genes whose expression increased or decreased more than
1.5-fold, upon treatment with HDACi 233 or HDACi 966. This
resulted in a final list of 88 genes of which 51 were uniquely up-
and 37 uniquely down-regulated by 109 (Table S2 in Supplemen-
tary Material). We then interrogated this final list for genes that
might be involved in chromatin structure or gene expression using
DAVID as above. Table 3 provides a list of 12 such genes, identified
by functional annotation clustering, although non-significantly
enriched in the 88 gene list. Two of these genes appeared to be
notable to us, namely histone H2A family member Y2 (H2AFY2)
and Polycomb group ring finger 2 (PCGF2). Each of these genes
is down-regulated selectively by HDACi 109 but not by the other
HDACi that fail to up-regulate FXN mRNA. H2AFY2 encodes a
macroH2A protein that has been implicated in X chromosome
inactivation, gene repression, and genomic imprinting [reviewed
in Ref. (41)]. PCGF2 is a negative regulator of developmentally
important genes, and specifically involved in H3K27 methylation-
mediated gene repression [reviewed in Ref. (42)]. To validate the
microarray data, we performed qRT-PCR for H2AFY2 and PCGF2
Table 3 | List of genes uniquely regulated by 109 and involved in gene
expression or chromatin structure.
Gene symbol Gene name
H2AFY2 H2A histone family, member Y2
PCGF2 Polycomb group ring finger 2
PLAGL1 Pleomorphic adenoma gene-like 1
MLXIPL MLX-interacting protein-like
ZNF586 Zinc finger protein 586
ABT1 Activator of basal transcription 1
ZFX Zinc finger protein, X-linked
PRKDC Similar to protein kinase, DNA-activated, catalytic
polypeptide
POU4F2 POU class 4 homeobox 2
POLE Polymerase (DNA directed), epsilon
ZNF92 Zinc finger protein 92
TRIM25 Tripartite motif-containing 25
mRNAs with RNA from neuronal cells that were treated with
each of the three HDAC inhibitors used in the microarray study.
Figure 5A shows that only compound 109 caused a significant
decrease in expression of both H2AFY2 and PCGF2. We then
asked if these results could be reproduced with a second series
of 4- and 5-substituted 2-aminobenzamides, namely, HDACi 136
and 3. Indeed, only an active compound similar to 109 (Click-
1, see below) was able to significantly down-regulate H2AFY2
and PCGF2 gene expression (Figure 5B), as predicted from the
microarray data and results with HDACi 966 and 233. While
HDACi 136 was moderately active at 10µM concentration (not
shown), it was inactive at lower concentrations and not as active
as HDACi 109 and Click-1 in down-regulating expression of these
two genes. Future studies will need to address whether these two
proteins, macroH2A and Polycomb group ring finger 2 are indeed
directly involved in FXN gene expression in FRDA neuronal cells.
However, the present data provide a correlation between HDACi
109 treatment, up-regulation of FXN, and down-regulation of
these two gene products.
DEVELOPMENT OF IMPROVED HDAC INHIBITORS FOR CLINICAL USE
Our first generation of molecules, such as 106,109, and derivatives,
suffer from two liabilities; namely, less than optimal brain penetra-
tion (0.15 brain to blood ratio) and conversion of the active mole-
cule into an inactive metabolic product in vivo (a benzimidazole).
FIGURE 5 | HDACi 109 down-regulates genes involved in chromatin
structure. (A) Effect of HDAC inhibitors 109, 233, and 966 on mRNA levels
for H2AFY2 (histone H2A family Y isotype 2, encoding macroH2A) and
PCGF2 (Polycomb group ring finger 2) in FRDA neuronal cells. Cells were
treated with the indicated compounds at 10µM for 24 h; RNA levels were
quantified by qRT-PCR and mRNA levels in the DMSO control was set to 1.
Error bars=SEM of triplicate measurements. **p<0.01. (B) Effect of
HDAC inhibitors Click-1, 3, and 136 on mRNA levels for H2AFY2 and PCGF2
in FRDA neuronal cells, as in (A), except the HDACi concentration was
5µM. **p<0.01.
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To circumvent these liabilities, we identified two structural fea-
tures that individually improve brain distribution and metabolic
stability of our HDAC inhibitors. Brain penetration is improved
by replacement of the “left” amide in the standard pimelic 2-
aminobenzamide scaffold (Figure 1) with an ether, olefin (alkene),
or ketone and introduction of a non-saturated α/β linkage adja-
cent to the“right”amide prevents formation of the benzimidazole.
Based on these results, we used Cu(I)-catalyzed click chemistry to
derive a small library of derivatives that combine these properties
(31) (Figure 6A). To determine whether such molecules retain
their ability to increase FXN mRNA in FRDA neuronal cells, we
compared the activity of one such molecule (Click-1) to that of
HDACi 109 (Figure 6B). Click-1 contains two unsaturated link-
ages, one adjacent to the 2-aminobenzamide amide linkage and
one replacing the “left” amide linkage in the original chemical
scaffold. Notably, this molecule contains a triazole, which is the
product of click chemistry. These changes to the HDACi scaffold
were completely tolerated as evidenced by equivalent activities of
HDACi 109 and Click-1 in the transcription assay (Figure 6B).
FIGURE 6 | HDAC inhibitors with improved pharmacological properties
yield comparable increases in FXN mRNA in FRDA neuronal cells as
the first-generation inhibitors. (A) Structures of compound 106 and
Click-1, showing replacement of the left amide in 106 with an unsaturated
bond, and introduction of a triazole in the linker region in Click-1. An
unsaturated bond was also introduced adjacent to benzamide to prevent
benzimidazole formation, as observed for 106 and other pimelic
2-aminobenzamides. (B) Quantitative RT-PCR was used to compare the
effects varying concentrations of HDACi 109 and Click-1 on FXN mRNA in
FRDA neuronal cells. mRNA levels were arbitrarily set to 1.0 for the DMSO
control. Error bars=SEM of triplicate measurements.
Given the improved pharmacology and specifically brain pene-
tration of this new class of compounds (31), these findings offer
promise for the development of a new generation of compounds
for human clinical studies in FRDA.
DISCUSSION
We recently demonstrated (28) that HDACi 109 is able to reverse
FXN gene silencing in FRDA neurons derived from patient iPSCs
to a degree comparable to that found in earlier studies employ-
ing human PBMCs and mouse models (5, 23, 26, 27). Brain
penetration and HDAC inhibition in the brain were established
in vivo in two mouse models for FRDA (23, 27). Our recent study
provided evidence for reversal of the heterochromatin state and
up-regulation of FXN mRNA and frataxin protein in human neu-
ronal cells. We also demonstrated HDAC inhibition and increased
H3K9 acetylation in PBMCs and an increase in FXN mRNA in
blood from patients treated with RG2833 (the drug formulation
product of 109). We demonstrated that combined HDAC1,2,and 3
inhibition is required to counteract the epigenetic changes induced
by the GAA•TTC repeat expansion and that H3K9 is a key histone
residue whose acetylation/methylation regulates FXN expression.
Compounds that are selective for particular class I HDACs do not
reactivate FXN gene expression to the extent found for HDACi 109
and also do not promote H3K9 acetylation to a similar degree.
In the current study, we extend our previous observation
that 4- and 5-substituted 2-aminobenzamides that are selec-
tive for HDAC3 or HDAC1, respectively, are relatively inactive
as inducers of FXN gene expression in FRDA neuronal cells
(28). We find that both HDACi 3 (this study) and 233 (28),
which both target HDAC1, are weakly active compared to HDACi
109 (28). Similarly, the HDAC3-selective compounds 136 (this
study) and 966 (28) are also inactive. HDACi 109 inhibits both
HDAC1 and HDAC3 through a slow-on/tight-binding mechanism
(mechanism 2 above), whereas the inactive 4- or 5-substituted
2-aminobenzamides do not share this property. For example,
HDACi 136 exhibits slow-on/tight-binding for HDAC3, but is
a fast-on/fast-off competitive inhibitor of HDAC1. Similarly,
HDACi 3 only shows slow-on/tight-binding for HDAC1. Highly
potent hydroxamate HDAC inhibitors such as SAHA and TSA are
rapid-on/rapid-off inhibitors and do not reactivate FXN expres-
sion in vitro (5, 22). Based on our results with small-molecule
inhibitors, we postulate that multiple HDACs may be responsi-
ble for FXN gene repression in FRDA, and that prolonged target
engagement may be required for reactivation. Interestingly, com-
binations of HDAC1/2- and HDAC3-selective inhibitors do not
reactive FXN gene expression (28), suggesting that reversal of
epigenetic silencing can only be achieved by inhibition of the
particular HDAC complexes residing at the FXN locus in FRDA
cells.
To corroborate our findings with small-molecule HDAC
inhibitors, we turned to siRNA silencing of class I HDACs. Strik-
ingly, we find that siRNAs to either HDAC1 or HDAC3 yield
comparable levels of FXN gene expression in FRDA neurons as
observed with HDACi 109 (Figure 3). This finding suggests to
us that the GAA•TTC repeat expansion may recruit a repressor
complex containing both enzymes. The interplay between HDACs
1 and 3 in neurodegenerative diseases is well established as well
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as the interaction between HDAC1 and HDAC3 in neuronal cells
[see for example Ref. (43)]. This suggestion would be in line with
the small-molecule inhibitor findings.
It is also possible that our HDAC inhibitors act indirectly on
the FXN gene by either up-regulating or down-regulating genes
encoding chromatin modifying enzymes or proteins involved
in chromatin structure. To assess this possibility, we analyzed
microarray data from FRDA neuronal cells treated with HDACi
109, 233, and 966. While approximately 1,200 genes are changed
in expression by treatment of these cells with HDACi 109, only
88 genes are uniquely regulated by 109, and not by 233 and 966.
Among these, 12 genes were found to be involved in DNA bind-
ing, chromatin structure, or gene expression. Inspection of this
list of genes (Table 3) revealed that two genes might be candi-
dates for regulators of FXN gene expression, namely H2AFY2
and PCGF2. Since the histone variant macroH2A, encoded by the
H2AFY2 gene, is known to be involved in gene repression (41),
down-regulation of this gene might well lead to increases in global
gene expression, as well as increases in FXN gene activity. Interest-
ingly, a recent study found that H2AY is specifically up-regulated
in Huntington’s disease (HD) postmortem brain and lymphoid
cells, and the levels of this mRNA are normalized by treatment of
HD patients in human clinical studies with the HDAC inhibitors
sodium butyrate and sodium phenylbutyrate (44). We find that
our 2-aminobenzamide HDACi are also effective in reversing the
global gene expression deficits in HD mouse models (29,45). These
findings may underpin a common mechanism of action of these
compounds in FRDA and HD.
Similar to macroH2A, Polycomb group ring finger 2 is involved
in transcriptional repression, being part of the Polycomb repres-
sive complex 1 (PRC1). PRC1 and Polycomb repressive complex
2 (PRC2) are recruited sequentially to target genes to repress their
expression (42). The components of PRC2, when recruited to tar-
get genes are responsible for the methylation of histone H3K27,
providing a binding site for the chromobox domain of compo-
nents of PRC1, which in turn catalyzes the monoubiquitination
of H2AK119. H3K27 trimethylation is enriched at the FXN gene
promoter and upstream and downstream of the GAA•TTC repeats
in FRDA neuronal cells (28), suggesting that Polycomb-mediated
repression may be involved inFXN gene silencing in FRDA. Hence,
down-regulation of the Polycomb silencing complex could well
lead to increases in FXN gene expression. Interestingly, a genome-
wide association study of macroH2A in pluripotent cells revealed
that its binding sites largely overlap with PRC2 binding sites (46).
Additionally, previous studies have documented down-regulation
of components of PRC2 with other HDAC inhibitors (47, 48).
Future ChIP and siRNA experiments will be needed to assess occu-
pancy of these gene products on FXN chromatin and the effects
of the inhibitors on such occupancy.
While our present and recent findings (28) provide a proof of
concept that patient-derived neuronal cells can be a quantitative
screening tool for the development of an epigenetic therapy for
FRDA, the compound used in our clinical study, 109/RG2833, suf-
fers from liabilities for chronic use as FRDA therapeutics; namely,
less than optimal brain penetration (0.15 brain to blood ratio),
and conversion of the active molecule into inactive, potentially
toxic metabolic products (benzimidazole and amidolysis) that
are poorly eliminated in vivo (31, 49). Other preclinical studies
placed RG2833 and the benzimidazole in the high-risk category for
inducing QTc prolongation (28). Given the cardiac involvement
in FRDA, molecules that produce this benzimidazole metabo-
lite are unlikely to be useful for chronic treatment of FRDA. We
therefore searched for chemical modifications to the pimelic 2-
aminobenzamide scaffold that would circumvent these liabilities.
As described earlier (31), replacement of the “left” amide in the
original scaffold (Figure 6A) with an ether, olefin, or double bond
was found to improve brain penetration. Similarly, introducing a
double bond adjacent to the benzamide prevented cyclization to
the benzimidazole. These chemical features were combined into a
small collection of derivatives by click chemistry (31), and com-
pound Click-1 was identified with improved brain penetration
(>0.7 brain/plasma ratio) and stability to benzimidazole forma-
tion. We now provide evidence that Click-1 retains its ability to
activate FXN gene expression in FRDA neuronal cells (Figure 6B),
with no loss of activity compared to HDACi 109. Thus, new deriv-
atives such as Click-1 and other variants are candidates for future
clinical studies in FRDA.
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